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Background: Epigenetic alterations such as microRNA (miRNA) and DNA 
methylation can regulate cancer cell properties in gastric cancer. miRNAs are an 
abundant class of negative gene regulators that control a wide range of biological 
functions such as cellular proliferation, differentiation and apoptosis by regulating 
multiple gene targets. miR-30a has been reported as a downregulated miRNA in 
gastric cancer, but its biological function and clinical implication have not been 
reported much. DNA methylation can repress transposable elements such as long 
interspersed nuclear element-1 (LINE-1), and LINE-1 is frequently hypomethylated 
in cancer. LINE-1 retrotransposition can generate many small RNAs such as 
miRNAs, and LINE-1 silencing is associated with miR-30a. 
Purpose: The aim of this study was to identify miR-30a expression and LINE-1 
methylation patterns as well as miR-30a biological function by finding its gastric 
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cancer-specific target genes. We also checked whether both miR-30a and LINE-1 
could be diagnostic or prognostic markers in gastric cancer by assessing the clinical 
impacts.  
Method: We performed qRT-PCR using our tissue samples to identify miR-30a and 
its target gene expressions. We used data from TCGA and NCBI GEO, to confirm 
their expressions in open source databases. To determine their biological functions, 
miR-30a was overexpressed by mimics or inhibited by inhibitors in gastric cancer 
cell lines. Moreover, a stable cell line overexpressing miR-30a was used for the in 
vivo tumorigenesis assay. Microarray was introduced to confirm the gastric cancer-
specific target gene of miR-30a, which was later knocked down by siRNA for 
functional studies. For LINE-1 methylation analysis, we examined four CpG sites of 
LINE-1 by quantitative bisulfite pyrosequencing using frozen and formalin-fixed 
paraffin-embedded (FFPE) tissues of gastric cancer. Finally, we analyzed the 
clinicopathological data.   
Result: In gastric cancer tissues, miR-30a was down-regulated, and LINE-1 was 
hypomethylated when compared to normal tissues. Ectopic expression of miR-30a 
decreased cell growth, migration capacity and colony formation in vitro and in vivo. 
Furthermore, we found that miR-30a directly targeted the ITGA2 gene and that the 
miR-30a-ITGA2 axis was significantly related to H. pylori-infected and 
microsatellite instability (MSI)-high gastric cancer. Higher expression of ITGA2 was 
particularly exhibited in intestinal type gastric cancer than in diffuse type gastric 
cancer. When we used both frozen and FFPE tissues for LINE-1 methylation analysis, 
LINE-1 was differentially methylated between two types of tissues. In frozen tissues, 
LINE-1 methylation status was different according to gender, differentiation, 
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lymphatic and venous invasions. In FFPE tissues, LINE-1 methylation was 
significantly different according to tumor location and venous invasion.  
Conclusion: Cumulatively, miR-30a functions as a tumor suppressor by directly 
targeting ITGA2. miR-30a-ITGA2 axis is related to several clinicopathological 
features of gastric cancer such as H. pylori, MSI and intestinal type. LINE-1, as one 
of miR-30a regulators, can be a marker according to its methylation status for several 
clinicopathological parameters, and especially it can be a marker for venous invasion 
in irrespective of gastric cancer tissue types. Therefore, we suggest that both miR-
30a-ITGA2 axis and LINE-1 may be useful strategies for treatment and prediction 
of prognosis in gastric cancer. LINE-1 study was published in Molecules and Cells 
in 2017, and figures and tables were reproduced and used in this paper [1]. 
Key word: Epigenetic alteration, miR-30a, tumor suppressor, ITGA2, LINE-1, 
venous invasion, gastric cancer  
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Introduction 
1. Gastric cancer and Epigenetic dysregulation 
Gastric cancer is the fifth most-common cancer and third leading cause of cancer-
related mortality worldwide [2]. Especially in Asian countries such as Korea, Japan 
and China, it is the second most common cause of cancer-related death [3]. 
Etiologically, gastric carcinogenesis can be induced by virus infection such as 
Helicobacter pylori (H. pylori) and Epstein-Barr, or hereditary and environmental 
factors are involved in the cause of gastric cancer [4]. Gastric cancer has been 
classified into several subtypes based on molecular characterization to encompass 
gastric cancer heterogeneity for clinical use [5, 6]. Also, to predict gastric cancer risk 
and prognosis, gene- or protein-based biomarker studies have been actively doing 
[7-9]. However, it is limited to develop comprehensive biomarker because the 
molecular mechanisms are complex and still poorly understood.  
Epigenetic alterations in cancer are mainly as follows; (i) Histone modifications 
such as methylation, acetylation and phosphorylation, (ii) DNA methylation, (iii) 
microRNA (miRNA) and non-coding RNA (ncRNA) [10]. Among these factors 
epigenetically affecting cancer, miRNAs, which are small non-coding RNA 
molecules consist of about 22 nucleotides, have been known as one of the most 
important biomarker related to gastric cancer progression and prognosis [11]. 
miRNAs function as regulators of transcriptional and translational silencing, then 
they repress gene expression [12, 13]. In cancer, miRNA dysregulation can be 
occurred during each step of its biogenesis by genetic and epigenetic alterations, 
hypoxia, mutations and so on [14]. Dysregulated miRNAs function as tumor 
suppressors or oncogenes in pre- or post-transcriptional silencing by binding 3’ UTR 
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region of its target mRNAs. Aberrant biogenesis of tumor suppressive miRNAs 
regulates cancer cell properties such as proliferation, angiogenesis and invasion by 
targeting oncogenic mRNAs [15]. For example, miR-200, miR-34 and let-7 are 
characterized as well-known tumor suppressors targeting cell fate-related genes or 
metastasis-inducing genes [16]. 
Retrotransposons can transcribe DNA to RNA via reverse transcription, then 
reintegrate identical DNA sequences into the genome. They are class I transposable 
elements which consist of long terminal repeats (LTRs) and non-LTRs including long 
interspersed nuclear element-1 (LINE-1), and non-LTRs are the majority of human 
transposable elements and affect human genome [17]. Many small RNAs including 
miRNAs are derived from repetitive sequences and retrotransposition activity of 
LINE-1, and these retrotransposon-derived small RNAs regulate gene expressions 
in specific tissues [18, 19]. Retrotransposition of LINE-1 can generate a significant 
number of small RNAs in the human genome [20]. LINE-1 constitutes a substantial 
portion (~17%) of the human genome [21]. LINE-1, which has two open reading 
frames, ORF1p and ORF2p, functions as a regulator of somatic retrotransposition, 
transcriptome effects and DNA damage [22]. Among epigenetic factors affecting 
cancer, DNA methylation in promoter CpG islands is associated with several 
processes such as repression of transposable elements and contribution to 
carcinogenesis by transcriptional silencing. So far, LINE-1 methylation has been 
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2. miR-30a and LINE-1 in cancer 
In the miRNA microarray data from four studies, miR-30a-5p has been one of 
downregulated miRNAs in gastric cancer [11, 23-25]. This miRNA functions as a 
suppressor of tumor growth via direct inhibition of DTL, MTDH or SEPT7 in colon 
cancer, breast cancer or glioma [26-28], and it also suppresses metastasis via 
targeting PIK3CD, ERG, MTDH or vimentin in colorectal, prostate or breast cancers 
[28-31]. In gastric cancer, a particular miRNAs signature including miR-30a-5p was 
useful to predict gastric cancer patient survival, with low risk score of miR-30a-5p 
[32]. In precancerous stage, it was reported that miR-30a was downregulated in 
intestinal metaplasia, and it caused overexpression of metaplastic marker genes 
through HNF4γ regulation [33]. In cancerous stage, only one target gene of miR-30a, 
vimentin, which is respective of metastasis was identified [34].  
miR-30 family consists of five members, miR-30a, -30b, -30c, -30d and -30e, and 
they have identical seed sequences. All other members except miR-30a have been 
also reported as negative regulators of tumor growth and metastasis in various type 
of cancers such as breast cancer, colorectal cancer, ovarian cancer and prostate 
cancer [28, 35-38]. In gastric cancer, miR-30b and miR-30c modulate cell migration 
and invasion by targeting EIF5A2 and MTA1 [39, 40]. Therefore, we focused on 
miR-30a-5p as one of critical tumor suppressors in gastric cancer. 
LINE-1 silencing increases several miRNAs including let-7 family, miR-196a, 
miR-30a/d, miR-191 and miR-200c in human breast cancer cells [41]. In addition, 
both LINE-1 and miR-30a are useful prognostic markers for gastric cancer [42]. 
Therefore, we additionally studied LINE-1 methylation as one of miR-30a regulatory 
factors in gastric cancer.  
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LINE-1 is often hypomethylated in cancers such as colon, bladder, breast and 
gastric cancer, and its hypomethylation is related to tumor progression and poor 
prognosis [43-46]. More concretely, in colorectal cancer, global LINE-1 
hypomethylation is inversely correlated with microsatellite instability (MSI) and 
worse overall survival [47-49], and it also triggers liver metastasis by inducing the 
MET proto-oncogene [50].  
In gastric neoplasia categorized according Vienna classification, LINE-1 was 
differentially methylated between low-grade dysplasia, high-grade dysplasia and 
intramucosal cancer, and it especially hypomethylated in high-grade dysplasia and 
intramucosal cancer [51]. LINE-1 hypomethylation has been reported to be 
associated with prognostic indicators in gastric carcinogenesis [44], and its 
methylation level can be changed on progressing from intestinal metaplasia to gastric 
adenoma, affecting gastric cancer poor prognosis [52].  
In a meta-analysis study including gastric cancer, LINE-1 is significantly 
hypomethylated in cancer patients compared to controls when it is analyzed using 
fresh/frozen and formalin-fixed paraffin-embedded (FFPE) tissue samples, but its 
methylation level is not different using blood samples [53]. Previously, LINE-1 
methylation analysis using 38 frozen and 434 FFPE tissue samples showed that 
LINE-1 methylation status significantly different between fresh/frozen tissues and 
FFPE tissues, and LINE-1 methylation in FFPE tissues was significantly associated 
with several clinicopathological features such as intestinal type, lymphatic invasion 
and venous invasion [54].    
However, thus far, it has not been studied to investigate the relation between 
clinicopathological features and LINE-1 methylation status in frozen tissue samples 
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of gastric cancer. Therefore, we analyzed LINE-1 methylation using both FFPE and 
frozen tissues to evaluate whether LINE-1 methylation can be an epigenetic marker 
for several clinicopathological parameters such as differentiation, tumor location, 
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Purpose of this study 
We hypothesized that miR-30a-5p can function as a tumor suppressor by regulating 
cancer cell properties through targeting several oncogenes in gastric cancer. 
Therefore, the aim of this study is to reveal miR-30a-5p expression pattern and 
biological function in gastric cancer and to find the miR-30a-5p target genes based 
on microarray technique. Also, the present study is to assess clinical impacts of miR-
30a-5p-target gene axis by discovering their functions in gastric cancer. Through 
these investigations, we would like to check whether the miR-30a-5p can use a 
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Material and method 
Cell lines and tissue specimens 
Four human gastric cancer cell lines, AGS, SNU-216, SNU-601 and MKN28, and 
human embryonic kidney (HEK293) cells were obtained from the Korean Cell Line 
Bank (Seoul, Korea) and maintained in RPMI 1640 (Welgene, Daegu, Korea) with 
10% Fetal bovine serum (Gibco, Invitrogen, UK) and 1% penicillin-streptomycin 
(Gibco, Invitrogen, UK). HSC44Luc, HSC45-M2 and 44As3Luc cell lines were 
provided by K Yanagihara, National Cancer Center Research Institute, Japan. They 
were cultured and maintained in the conditions same as above gastric cancer cell 
lines. Thirty pairs of primary gastric cancer tissues and matched normal mucosa were 
used to analyze miRNA or mRNA expression levels. All tissue specimens were 
obtained from Seoul National University Hospital, Korea. The clinicopathological 
features of the patients are summarized in Table 1. The present study was approved 
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Table 1. Clinicopathological features of 30 patients with gastric cancer 
 
Characteristic Gastric cancer (n=30) Percentage 
Gender   
Male 22 73.33% 
Female 8 26.67% 
    
Age, years   
≤ 61 14 46.67% 
> 61 16 53.33% 
    
T classification   
T1 2 6.67% 
T2 4 13.33% 
T3 11 36.67% 
T4 13 43.33% 
   
N classification   
N0 8 26.67% 
N1 3 10.00% 
N2 9 30.00% 
N3 10 33.33% 
    
Distance metastasis   
Absent 23 76.67% 
Present 7 23.33% 
   
TNM stage   
I 6 20.00% 
II 8 26.67% 
III 7 23.33% 
IV 9 30.00% 
    
Lauren Classification   
Intestinal 18 60.00% 
Diffuse                10 33.33% 
Mixed 2 6.67% 
   
WHO classification   
Differentiated  16 53.33% 
Undifferentiated 14 46.67% 
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Tumor location   
Upper 8 26.67% 
Middle 10 33.33% 
Lower 12 40.00% 
   
Lymphatic invasion   
Not identified 10 33.33% 
Present 18 60.00% 
Unknown 2 6.67% 
   
Venous invasion   
Not identified 23 76.67% 
Present 5 16.67% 
Unknown 2 6.67% 
   
Perineural invasion   
Not identified 14 46.67% 
Present 14 46.67% 
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Computational analysis 
We used public databases such as the NCBI Gene Expression Omnibus (GEO) and 
The Cancer Genome Atlas (TCGA). miRNA and mRNA expression data were 
obtained by RNA sequencing (RNAseq) of each database. In the GEO database, we 
used miRNA expression data of 8 non-cancer and 60 primary gastric cancer 
(GSE26595). In TCGA, miRNA expression data of 42 normal and 476 stomach 
cancer was generated using the Illumina GA HiSeq, and gene expression data of 37 
normal and 384 stomach cancer was generated using the Illumina HiSeq. Also, 
prediction programs such as TargetScan, PITA and miRanda were applied for 
identifying candidate target genes of miR-30a. 
 
Transfection using miR-30a mimic, miR-30a inhibitor, stable 
miR-30a-expressing vector and ITGA2 siRNA 
For transient induction or inhibition of miR-30a, we transfected miR-30a mimics or 
miR-30a inhibitor with their negative controls (Bioneer, Korea) into gastric cancer 
cells. To establish gastric cancer cell line stably expressing miR-30a, the full-length 
coding region of miR-30a cDNA was amplified from normal genomic DNA and 
cloned into the pmR-ZsGreen1 vector (Clontech, Japan). Stable cell line was 
generated by transfection of plasmids into SNU-601 cells and selection of miR-30a-
expressing clones by Geneticin (G418). Primers are described in Table 2. For 
transient knockdown of ITGA2, siRNAs for ITGA2 (Bioneer, Korea) were 
transfected into gastric cancer cell lines. Transient transfections of miRNA or si-
RNA were performed using Lipofectamine RNAiMAX (Invitrogen), and plasmid 
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transfection was carried out using Lipofectamine 3000 (Invitrogen) following the 
manufacturer’s instructions. 
 
Cell proliferation, soft agar colony formation and migration 
assays 
Cell proliferation assay was performed in AGS, SNU-601, SNU-216 and SNU-668 
cell lines using Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan) at 
absorbance 450nm for 72 h. For soft agar colony formation assay, base agar were 
seeded into 6-well plates, and transfected cells (1×104 cells/well) with top agar were 
seeded on the base agar at triplicate. The plates were incubated for 4 weeks. Colonies 
were stained with Crystal violet (Sigma-Aldrich, St. Louis, Missouri, USA) and 
counted under the microscope. 
Migration assay was performed with Boyden chambers (BD Biosciences) that had 
8um pore size membranes. Cells were seeded into upper chamber (2×105 cells/well). 
After 18 h, cells were stained with Crystal violet (Sigma-Aldrich, St. Louis, Missouri, 
USA) and counted under the microscope to calculate relative migration rates. 
 
Microarray 
SNU-601, HSC44Luc and 44As3Luc cells were transfected with miR-30a mimic or 
NC mimic using RNAiMAX reagent (Invitrogen). Total RNA was extracted by 
TRIzol reagent (Invitrogen). RNA purity and integrity were evaluated by ND-1000 
Spectrophotometer (NanoDrop, Wilmington, USA) and Agilent 2100 Bioanalyzer 
(Agilent Technologies, Palo Alto, USA). Total RNA was amplified and purified 
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using TargetAmp-Nano Labeling Kit for Illumina Expression BeadChip 
(EPICENTRE, Madison, USA) to yield biotinylated cRNA according to the 
manufacturer’s instructions. Briefly, 500 ng of total RNA was reverse-transcribed to 
cDNA using a T7 oligo(dT) primer. Second-strand cDNA was synthesized, in vitro 
transcribed and labeled with biotin-NTP. After purification, the cRNA was quantified 
using the ND-1000 Spectrophotometer (NanoDrop, Wilmington, USA). 750 ng of 
labeled cRNA samples were hybridized to each Human HT-12 v4.0 Expression 
Beadchip for 17h at 58°C, according to the manufacturer's instructions (Illumina, 
Inc., San Diego, USA). Detection of array signal was carried out using Amersham 
fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) 
following the bead array manual. Arrays were scanned with an Illumina bead array 
Reader confocal scanner according to the manufacturer's instructions. The quality of 
hybridization and overall chip performance were monitored by visual inspection of 
both internal quality control checks and the raw scanned data. Raw data were 
extracted using the software provided by the manufacturer (Illumina GenomeStudio 
v2011.1 (Gene Expression Module v1.9.0)). Array probes transformed by logarithm 
and normalized by quantile method. 
 
Luciferase reporter assay 
A fragment containing ITGA2 3’UTR was amplified and cloned into the pmirGLO 
Dual-Luciferase miRNA target expression vector (Promega, USA). Primers are 
described in Table 2. Luciferase reporter vectors were transfected into the cells, and 
luciferase activity was measured using the Dual-Luciferase®  Reporter Assay System 
following the manufacturer’s instructions.  
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Quantitative real-time PCR (qRT-PCR) 
Total RNA was isolated from cell lines and tissue samples using Trizol reagent 
(Invitrogen, Carlsbad, USA) or miRNeasy Mini Kit (QIAGEN). cDNA was 
synthesized to analyze both mRNA and microRNA expressions using a TOP script 
cDNA synthesis kit (Enzynomics, Daejeon, Korea) or PrimeScript RT reagent kit 
(Takara) according to the manufacturer’s protocols. The expression level of miR-30a 
was measured using SYBR Green Master Mix (Applied Biosystems, Carlsbad, CA) 
by normalizing to the levels of U6. Also, the mRNA expression levels were 
quantified by normalizing to GAPDH. Primers are indicated in Table 2. All the 
reaction were performed and analyzed by comparative △△Ct methods using Step 
One Plus Real-Time PCR system (Applied Biosystems, Carlsbad, CA). 
 
Western blotting 
Cells were washed with cold PBS and lysed with RIPA buffer (ThermoFisher 
Scientific, MA, USA) plus protease inhibitor cocktails (Roche). Proteins were 
isolated from cell lysates, and western blotting was performed using anti-ITGA2 
(1:2000, Abcam, Cambridge, UK), anti-α-tubulin (1:1000, Sigma-Aldrich, St. Louis, 
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Table 2. Primers for stable miR-30a expressing vectors, gene expression 
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In vivo experiments 
Female BALB/c nu/nu mice, at age of 6-8 weeks (Orient Bio., Sungnam, Korea), 
were used to establish tumor xenograft models. For tumorigenicity assay, we 
subcutaneously injected empty vector transfected (n=8) or stably miR-30a 
overexpressed (n=8) SNU-601 cells into the right flank of nude mice. 1×107cells in 
200 μl of medium were injected into each mice. Tumor size was measured using 
calipers twice every week, and the tumor volume was calculated by lenghth (L) × 
width (W) × height (H). At day 63, all mice was sacrificed, and tumor mass was 
pathologically checked by hematoxylin and eosin (H&E) staining. This animal 
experiment was approved by the Institutional Animal Care and Use Committee 




For evaluation of the expression profiles of ITGA2 protein, a collection of 450 
gastric adenocarcinomas resected at SNUH in 2004 (SNUH-2004-GC; 
SuperBioChips) was used. Immunohistochemical staining was performed 
automatically using OPTIVIEW universal DAB kit on Ventana BenchMark XT 
Staining systems (Ventana Medical Systems). Tumor tissues were selected in each 
core, and a scoring was performed based on a staining intensity. The staining was 
considered as positive if more than 10% of cellular staining was observed in each 
core. The staining intensity was as follows: 0, negative; 0.5, faint positive; 1, weak 
positive; 2, moderate positive; 3, strong positive.  
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Statistical analysis 
Student t-test was used to compare gene expression and functions such as cell 
proliferation and migration. In vivo experiment, two-way ANOVA was tested to 
evaluate tumor volume changes. To assess correlation between miR-30a and target 
genes, the Spearman’s correlation test was conducted. These statistical analyses were 
performed using GraphPad Prism V5.0 (GraphPad Software, San Diego, CA). A p-
value was considered as statistically significant when it was less then 0.05. 
Significant differences were indicated by asterisks: *p < 0.05, ** p < 0.01, *** p < 
0.001. 
For microarray, statistical significance of the expression data was determined using 
Independent T-test and fold change in which the null hypothesis was that no 
difference exists among groups. False discovery rate (FDR) was controlled by 
adjusting p value using Benjamini-Hochberg algorithm. For a differentially 
expressed gene (DEG) set, Hierarchical cluster analysis was performed using 
complete linkage and Euclidean distance as a measure of similarity. Gene-
Enrichment and Functional Annotation analysis for significant probe list was 
performed using DAVID (http://david.abcc.ncifcrf.gov/home.jsp). All data analysis 
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Result 
Expression level of miR-30a-5p in gastric cancer 
We analyzed expression patterns of miRNA family in gastric cancer using RNA 
sequencing data of stomach adenocarcinoma from The Cancer Genome Atlas 
(TCGA). Among them, expressions of several miR-30 family members were distinct 
between normal and tumor. Unlike other members, miR-30a and miR-30e were 
particulary highly expressed in normal, and their low expressions in lots of tumor 
were shown (Figure 1 and Table 3). We performed quantitative real-time PCR using 
our gastric cancer tissue cohort. miR-30a expression was validated in 30 pairs of 
gastric cancer tissues, and it was significantly down-regulated in 25 pairs of gastric 
cancer tissues compared to matched normal mucosa (Figure 2A). We also applied 
another computational analysis using public data, NCBI Gene Expression Omnibus 
(GEO) database, with TCGA data. TCGA data showed that miR-30a is quite down-
regulated in gastric tumor (n=476) compared with normal (n=42), and NCBI GEO 
data indicated the same pattern (gastric adenocarcinoma; n=60, non-cancer; n=8) 
(Figure 2B and 2C). Therefore, we suggest that miR-30a-5p is a potential tumor 
















Figure 1. Expression of miR-30 family in normal and stomach adenocarcinoma 
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miR-30 family Normal Tissue (n=42) Primary Tumor (n=476) P value 
miR-30a 14.36 ± 0.10 13.52 ± 0.05 < 0.001 
miR-30b 8.30 ± 0.17 8.53 ± 0.04 0.106 
miR-30c-1 1.01 ± 0.07 1.27 ± 0.03 0.008 
miR-30c-2 8.93 ± 0.13 8.81 ± 0.03 0.291 
miR-30d 11.96 ± 0.07 12.29 ± 0.03 0.002 
miR-30e 13.24 ± 0.10 13.01 ± 0.03 0.031 












                       









Figure 2. miR-30a expression between normal and tumor tissues in our cohort 
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miR-30a can function as a tumor suppressive miRNA in gastric 
cancer 
In gastric cancer cell lines, it was expressed differentially between 6 cell lines 
(Figure 3A), so we treated miR-30a mimic or inhibitor in these cells for further in 
vitro study to test whether miR-30a can function as a tumor suppressor gene in 
gastric cancer. As a control, negative controls of miR-30a mimic or miR-30a 
inhibitor were treated in the same conditions. The induction or inhibition of miR-30a 
was confirmed as shown in Figure 3B and 3C. 
Cell proliferation was reduced when we treated miR-30a mimic (Figure 4). Soft 
agar colony formation assay showed similar result, and the differences were 
statistically significant. In contrast, cells treated with miR-30a inhibitor formed 
much more colonies than its control group (Figure 5). Based on these data, we 
subcutaneously injected SNU-601 cells stably overexpressing miR-30a or empty 
vector into BALB/c nude mice. Each group consisted of eight mice. During 63 days, 
tumor volume had been significantly reduced in miR-30a group than in control group 
before sacrificed (Figure 6). Thus, it shows that miR-30a effectively suppressed 
tumorigenesis of gastric cancer cells both in vitro and in vivo. 
To confirm the effects of miR-30a on cell movements, cells treated with negative 
control or miR-30a mimic were observed in time-based monitoring after cell seeding 
in Boyden chambers. The number of migrated cells through Boyden chamber was 
significantly decreased in miR-30a mimic treated group compared to negative 
control (Figure 7). These results implies that this miRNA is an effective factor to 
inhibit cell migration in gastric cancer. 
 










































































Figure 3. Relative expression level of miR-30a-5p in gastric cancer cell lines. 
Expression screening using 6 gastric cancer cell lines (A) and its relative expression 
level after miR-30a mimic or miR-30a inhibitor treatments compared negative 
























































































































Figure 4. Cell proliferation assay (WST assay). The absorbance of 450nm was 
measured at 72hr after transient transfection in SNU-601 (A), HSC44Luc (B) and 




















































































































Figure 6. in vivo tumorigenesis assay using nude mice. Stable cell lines 
overexpressing empty vector (NC) or miR-30a were subcutaneously injected into 






















































































Figure 7. Transwell migration assay 
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miR-30a affects downregulations of ITGA2, FBXO45, 
ADAM19 and SEC23A in gastric cancer  
 Novel miR-30a candidate target genes were revealed by microarray analysis. We 
identified differentially expressed genes between NC mimic- or miR-30a mimic- 
treated three gastric cancer cell lines, SNU-601, HSC44Luc, 44As3Luc (Figure 8). 
We considered that downregulated genes in miR-30a mimic-treated cells may be 
negatively regulated by miR-30a. Therefore, as shown in Figure 9, we figured out 
overlapped genes in more than two cell lines. Then, these genes were confirmed 
using miRNA target gene prediction program such as TargetScan, PITA and miRanda 
whether these genes are candidate target genes of miR-30a or not. We finally selected 
ITGA2, FBXO45, ADAM19 and SEC23A as genes downregulated by miR-30a 
because their expressions were significantly reduced by miR-30a mimic compared 
to negative control when we validated expressions of these genes in each cell line 
using qRT-PCR (Figure 10). Thus, miR-30a downregulates ITGA2, FBXO45, 























Figure 8. Heat map for differentially expressed genes from microarray data. 
Negative control mimic (NC) or miR-30a mimic (miR-30a) were treated into SNU-


























Figure 9. miR-30a candidate target genes. miR-30a candidate target genes which 
were downregulated in miR-30a mimic-treated cells compared to control from 
microarray data (left) and which have miR-30a binding sites confirmed using 
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ITGA2 is directly targeted by miR-30a in gastric cancer 
 In order to determine associations of each four gene with miR-30a, we screened 
their expressions in both TCGA cohort and 30 pairs of gastric cancer tissues as the 
same cohort used for miR-30a expression screening. In TCGA data, ITGA2, 
FBXO45 and ADAM19 expressions were significantly higher in tumor than in 
normal (Figure 11A), and expressions of ITGA2 and FBXO45 were inversely 
correlated with miR-30a expression (Figure 11B). In our cohort, only ITGA2 was 
significantly upregulated in gastric cancer compared to their matched normal mucosa 
even though FBXO45, ADAM19 and SEC23A expressions were not different 
(Figure 12A). Also, it was inversely correlated with miR-30a expression (Figure 
12B). Therefore, HEK293T cells were transiently transfected with plasmids 
containing wild-type of ITGA2 3’ UTR or mutant-type of ITGA2 3’ UTR regions to 
confirm whether miR-30a can directly interact with ITGA2. miR-30a binding site of 
ITGA2 was shown in Figure 13A. When miR-30a mimic was cotransfected, 
luciferase activity was lesser in cell lysates containing luciferase vector inserted 
wild-type ITGA2 3’ UTR than in negative control. However, miR-30a didn’t interact 
with mutant-type ITGA2 3’ UTR (Figure 13B). According to these results, miR-30a 
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Figure 11. ITGA2, FBXO45, ADAM19 and SEC23A expression analysis using 
TCGA data. Their expressions between 37 normal (N) and 384 tumor (T) tissues 
were analyzed using RNA sequencing data of TCGA (A). ITGA2 and FBXO45 were 
















































Figure 12. ITGA2, FBXO45, ADAM19 and SEC23A expression analysis using 
our cohort. Analysis of ITGA2, FBXO45, ADAM19 and SEC23A expressions in 
30 pairs of gastric cancer tissues (GC) and adjacent normal mucosa (NM) using qRT-
PCR (A) and correlation between miR-30a and ITGA2 expressions (B) 
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Figure 13. Luciferase reporter assay. Reporter constructs containing the wild type 




Luciferase PGK promoter 5’ 3’ 
SacI XhoI 
Target gene 3’UTR 
miR-30a 
5' ..CAGGGCUAUCUGUACUGUUUACA... 
           
3'     GAAGGUCAGCUCCUACAAAUGU 
WT ITGA2 3’UTR 
miR-30a 
5' ...CAGGGCUAUCUGUACUGAAAAAA... 
           
Mut ITGA2 3’UTR 
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ITGA2 knockdown suppresses gastric cancer cell properties  
 So far, ITGA2 function has been few studied in gastric cancer. Because ITGA2 is 
a direct target of miR-30a in this study, we treated siRNA for ITGA2 in gastric cancer 
cell lines to confirm the effects on its suppression in gastric cancer cell growth or 
motility. As shown in Figure 14A, ITGA2 was differentially expressed in six gastric 
cancer cell lines. Then, we treated two siRNAs targeting ITGA2 transcript in SNU-
601 and 44As3Luc cells and identified the suppression of both mRNA and protein 
levels that much less than half of negative control (Figure 14B). Cell proliferation 
was significantly reduced in these two cell lines at 24hr, 48hr and 72hr following 
siRNA treatments (Figure 15). Also, colony formation ability was quite suppressed 
in siRNA-treated cells compared to negative control (Figure 16). Since miR-30a 
regulation affected to cell migration, we also measured migrated cells after si-ITGA2 
treatment. As shown in Figure 17, ITGA2 knockdown led to significant reduction of 
migrated cells compared to control cells. These data revealed that ITGA2 
















































































Figure 14. Relative expression level of ITGA2 in gastric cancer cell lines. ITGA2 
transcript level in 6 gastric cancer cell lines (A) and its mRNA and protein 
knockdown by two siRNAs (si-ITGA2 #1 and #2) in SNU-601 and 44As3Luc cells 
compared to negative control siRNA (NC) (B) 







































































































































Figure 15. Cell proliferation assay (WST-assay). The absorbance at 450nm was 





















































Figure 16. Soft agar colony formation assay. The anchorage independent cell 





















NC si-ITGA2 #1 si-ITGA2 #2 










































Figure 17. Transwell migration assay. Relative migrated cells were counted 



















NC si-ITGA2 #1 si-ITGA2 #2 
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Clinicopathologic and prognostic relevances of miR-30a-
ITGA2 expression in gastric cancer patients 
To investigate whether miR-30a and ITGA2 expressions can be biomarkers for 
clinicopathological parameters in gastric cancer, we first analyzed clinical 
information from NCBI GEO data and TCGA cohort. In NCBI GEO data, the 
significant downregulation of miR-30a was observed in H. pylori-infected gastric 
cancer. In contrast, ITGA2 was significantly upregulated in H. pylori-infected 
intestinal metaplasia compared to H. pylori-not infected normal (Figure 18). We 
additionally analyzed both miR-30a and ITGA2 expressionis according to MSI, H. 
pylori infection, histological type, lymph node metastasis and TNM stage from 
TCGA data. As shown in Figure 19A, miR-30a was more downregulated in MSI-
high compared with both microsatellite stability (MSS) and MSI-low types, and the 
opposite result was obtained from ITGA2. There were inverse correlations between 
miR-30a and ITGA2 in each MSS and MSI-high type (Figure 19B). Also, we 
observed significantly lower mean value of miR-30a in intestinal type gastric cancer 
than in diffuse type gastric cancer, while ITGA2 was upregulated in intestinal type 
(Figure 20A). They were also inversely correlated each other in each histological 
type (Figure 20B). In our cohort, miR-30a expression was not different between 
intestinal and diffuse type, but ITGA2 was significantly upregulated in intestinal 
type (Figure 21A). It also had inverse correlation with miR-30a in intesitnal type 
(Figure 21B).   
Next, we conducted pathological examination using tissue microarray (TMA) to 
evaluate associations between ITGA2 and clinical implications. In the result of TMA, 
membranous or cytoplasmic expressions of ITGA2 were identified, and each 
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expression was individually scored in the range of negative (score 0) to strong 
positive (score 3) as shown in Figure 22. We analyzed each score according to 
clinical features such as TNM stage, histological type, differentiation status and 
patient survival. Cytoplasmic ITGA2 was associated with only lauren classification, 
but there were no significant diffences between all of clinicopathological features 
and membranous ITGA2 expression. Stronger staining intensities of cytoplasmic 
ITGA2 tended to be included more in intestinal type gastric cancer than in diffuse 
type gastric cancer, and the difference was statistically significant (Figure 23). These 
data indicated that miR-30a can be a biomarker for H. pylori infection and revealed 
that miR-30a-ITGA2 axis is useful to predict both MSI and lauren classification in 
gastric cancer. Especially in protein level, ITGA2 expression in cytoplasm could be 
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Figure 18. miR-30a-5p and ITGA2 expressions according to H. pylori infection. 
miR-30a-5p expression in H. pylori-infected (H.P (+), n=9) or -not infected (H.P (-), 
n=10) gastric cancer analyzed from GSE19769 (A) and ITGA2 expression in H.P (-) 
normal (n=8), mild gastritis (n=8), severe gastritis (n=8) and intestinal metaplasia 
(IM, n=8) analyzed from GSE60427 data (B) of NCBI GEO 
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Figure 19. miR-30a and ITGA2 expression analysis (A) and correlation analysis 
(B) according to MSI. Expression and correlation analyses were performed 
according to MSS (n=307), MSI-low (MSI-L, n=63) and MSI-high (MSI-H, n=88) 
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Figure 20. miR-30a and ITGA2 expression analysis (A) and correlation analysis 
(B) according to Lauren classification using TCGA data. Expression data 























































Figure 21. miR-30a and ITGA2 expression analysis (A) and correlation analysis 
(B) according to Lauren classification using our cohort. Analyses according to 
diffuse type (n=12) and intestinal type (n=18) gastric cancer from our cohort. 





















































































Figure 22. The representative results of ITGA2 immunohistochemical staining. 





















Figure 23. ITGA2 cytoplasmic expression according to Lauren classification. 
Intestinal type gastric cancer (n=172) had higher mean value of TMA score than 













Long interspersed nuclear element-1 (LINE-1), one of 
miR-30a regulators, is associated with 
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Purpose of this study 
 We hypothesized that LINE-1 would be a prognostic marker in different tissue types 
of gastric cancer. Therefore, the aim of this study is to validate LINE-1 methylation 
pattern in two gastric cancer tissue types, formalin-fixed paraffin-embedded (FFPE) 
and frozen tissues, and to evaluate whether LINE-1 methylation can be an epigenetic 
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Material and method 
Tissue specimens 
Forty-one pairs of primary gastric cancer tissues and corresponding normal mucosa 
were immediately frozen in liquid nitrogen without fixation following gastrectomy, 
and tumor cellularity was confirmed by a pathologist. Twenty-five tumor tissues 
were fixed with formalin and embedded in paraffin, and only tumor area was 
confirmed by a pathologist. The clinicopathological characteristics of total 66 
patients are indicated in Table 4. LINE-1 methylation status was analyzed according 
to gender, age, WHO classification, Lauren classification, tumor location, lymphatic 
invasion, venous invasion, perineural invasion, TNM stage and MSI. Tissue 
specimens and written informed consent from all patients were obtained from Seoul 
National University Hospital, Korea. This study was approved by the institutional 
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Table 4. Clinicopathological features of 66 gastric cancer patients 
Characteristic Gastric cancer (n=66) Percentage 
Gender   
Male 42 63.64% 
Female 24 36.36% 
    
Age, years   
≤ 59 31 46.97% 
> 59 35 53.03% 
    
T classification   
T1 12 18.18% 
T2 14 21.21% 
T3 21 31.82% 
T4 19 28.79% 
   
N classification   
N0 28 42.42% 
N1 7 10.61% 
N2 8 12.12% 
N3 23 34.85% 
    
Distance metastasis   
Absent 62 93.94% 
Present 4 6.06% 
   
TNM stage   
I 0 0.00% 
II 49 74.24% 
III 13 19.70% 
IV 4 6.06% 
    
Lauren Classification   
Intestinal 28 42.42% 
Diffuse                27 40.91% 
Mixed 2 3.03% 
Unknown 9 13.64% 
   
WHO classification   
Differentiated 24 36.36% 
Undifferentiated 35 53.03% 
Unknown 7 10.61% 
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Tumor location   
Upper 16 24.24% 
Middle 13 19.70% 
Lower 36 54.54% 
Entire 1 1.52% 
   
Lymphatic invasion   
Not identified 22 33.33% 
Present 25 37.88% 
Unknown 19 28.79% 
   
Venous invasion   
Not identified 40 60.61% 
Present 7 10.61% 
Unknown 19 28.79% 
   
Perineural invasion   
Not identified 28 42.42% 
Present 19 28.79% 
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DNA extraction and sodium bisulfite modification 
Genomic DNA (gDNA) was extracted from frozen tissues using the QuickGene 
DNA tissue kit S with QG-Mini80 (Kurabo, Japan) and from FFPE tissues using the 
QIAamp DNA Mini Kit (Qiagen, Germany) according to the manufacturer’s 
protocols. Sodium bisulfite modification of 600 ng DNA was performed using the 
EpiTect Bisulfite Kit (Qiagen, Germany) according to the manufacturer’s 
instructions. The reaction was set under following conditions: 5 min at 95℃, 25 min 
at 60℃, 5 min at 95℃, 85 min at 60℃, 5 min at 95℃, 175 min at 60℃, and overnight 
at 20℃. The final products were stored at -20℃ until further use. 
 
Quantitative bisulfite pyrosequencing for LINE-1 and 
methylation analysis 
Bisulfite pyrosequencing for LINE-1 was performed as previously described [55]. 
PCR reaction was conducted in a volume of 20 μl, with ≥20 ng bisulfite modified 
gDNA, PCR premixture (Enzynomics, Korea), 10 pmol/μl forward and biotinylated 
reverse primers. The reaction was performed according to the following conditions: 
10 min at 95℃; followed by 45 cycles at 95℃ for 30 s, 53℃ for 30 s, and 72℃ for 
30 s; and 5 min at 72℃. The 2 μl of PCR products were loaded by electrophoresis 
using a 2% agarose gel with ethidium bromide. A single-stranded DNA template was 
prepared from 16-18 μl of the biotinylated PCR product using streptavidin 
Sepharose HP beads (Amersham Biosciences, Sweden) following the PSQ 96 
sample preparation guide. Sequencing was performed on a PyroMark ID system with 
a Pyro Gold reagents kit (Qiagen) according to the manufacturer’s instructions 
without further optimization, and 15 pmol/μl sequencing primer was used for 
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analysis. The primers are described in Table 5. The average of LINE-1 methylation 
level was calculated from the methylation percentage at 4 CpG sites. In Figure 24, 
four CpG sites of LINE-1 that we analysed in this study were indicated. Patients 
were grouped according to each clinicopathological parameter to compare LINE-1 
methylation levels. In all clinicopathological parameters, the average methylation 
percentage of all CpG sites and each four CpG site were analysed. 
 
Statistical analysis 
To compare the LINE-1 methylation levels in frozen 41 pairs of gastric cancer and 
matched normal mucosa, a paired t-test was performed. An unpaired t-test was used 
to compare LINE-1 methylation between each classified groups according to 
clinicopathological parameters. The ANOVA test was used in analysis of the tumor 
location and TNM Stage. Statistically significant difference was considered at p-
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Primer Sequence (5’  3’) 
Forward primer for PCR TTTTGAGTTAGGTGTGGGATATA 
Reverse primer for PCR  Biotin-AAAATCAAAAAATTCCCTTTC 
Sequencing primer AGTTAGGTGTGGGATATAGT 
- 57 - 
 
 












- 58 - 
 
Result 
Validation of LINE-1 methylation patterns in frozen and 
FFPE tissues of gastric cancer 
As previously reported, LINE-1 methylation percentages are different between 
fresh tissue and FFPE tissue [54]. Accordingly, we validated its methylation levels 
at four CpG sites of the LINE-1 promoter using our frozen and FFPE tissue samples. 
The average methylation level of LINE-1 was significantly different between 41 
frozen tumor tissues and 25 FFPE tumor tissues (p < 0.001, Figure 25A). When we 
compared methylation level at each CpG site, LINE-1 was significantly 
hypermethylated at CpG3 and CpG4 of FFPE tumor tissues compared to those of 
frozen tumor tissues (CpG3; p < 0.001, CpG4; p < 0.001, Figure 25B). In each tissue 
type, LINE-1 methylation levels were different at each CpG site (Figure 25C and 
25D). These results verified LINE-1 methylation status differed between each CpG 
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Figure 25. LINE-1 methylation levels in frozen and FFPE tumor tissues. The 
average methylation level of all CpG sites (A), the methylation level at each CpG 
site (B) between frozen and FFPE tumor tissues and LINE-1 methylation level at 
each CpG site in frozen tumor tissues (C) and in FFPE tissues (D) 
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Analysis of LINE-1 methylation and clinicopathological 
characteristics using frozen tissues  
To validate whether LINE-1 hypomethylation is shown in our gastric cancer tissue 
samples before we analyze association between LINE-1 methylation and 
clinicopathological parameters, 41 pairs of gastric cancer tissues and corresponding 
normal mucosa were used. As shown in Figure 26, LINE-1 was significantly 
hypomethylated in gastric cancer compared to normal mucosa (p < 0.001). Next, we 
compared LINE-1 methylation levels according to age, gender, WHO classification, 
Lauren classification, tumor location, lymphatic invasion, perineural invasion, TNM 
stage and MSI. As shown in Figure 27, LINE-1 was hypomethylated in the male 
gender (p = 0.004), differentiated gastric cancer (p = 0.016), the presence of 
lymphatic invasion (p = 0.023) and venous invasion (p = 0.016). Therefore, we 
additionally analyzed the methylation level at each CpG site. In gender, 
differentiation status, lymphatic invasion and venous invasion, LINE-1 methylation 
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Figure 27. LINE-1 methylation levels according to gender (A), differentiation 
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Table 6. The methylation level of LINE-1 at four CpG site according to 
clinicopathological characteristics of frozen tumor tissues 
Characteristic No 
LINE-1 methylation level (%) 
CpG 1 P value CpG 2 P value CpG 3 P value CpG 4 P value 
Type          
Normal mucosa 41 81.61 <0.001 78.27 <0.001 76.32 <0.001 80.48 <0.001 
Gastric cancer 41 70.73  71.32  68.74  71.76  
          
Age          
≤61 18 70.82 0.965 73.48 0.157 71.12 0.189 74.13 0.215 
>61 23 70.66  69.62  66.88  69.90  
          
Gender          
Male 30 68.42 0.021 69.19 0.007 65.69 <0.001 69.12 0.008 
Female 11 77.02  77.12  77.07  78.95  
          
WHO classification 
Differentiated 18 66.32 0.017 67.38 0.012 64.53 0.036 67.10 0.020 
Undifferentiated 20 74.77  74.53  71.53  75.34  
          
Lauren classification 
Intestinal 20 67.18 0.199 68.40 0.252 65.25 0.211 68.14 0.214 
Diffuse 12 72.53  71.97  70.02  73.12  
          
Tumor location          
Upper 11 69.59 0.887a 68.70 0.295a 65.29 0.296a 68.12 0.207a 
Middle 8 69.85  75.02  72.80  77.04  
Lower 21 71.40  70.93  68.88  71.31  
          
Lymphatic invasion 
Not identified 11 75.53 0.041 74.28 0.020 72.00 0.020 75.35 0.029 
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Present 11 65.28  66.17  61.65  65.60  
          
Venous invasion          
Not identified 18 72.86 0.037 72.20 0.016 69.34 0.016 73.06 0.012 
Present 4 59.36  61.36  55.50  58.82  
          
Perineural invasion 
Not identified 16 70.90 0.757 70.87 0.570 67.35 0.716 71.11 0.659 
Present 6 69.07  68.51  65.41  68.77  
          
TNM stage          
II 26 70.92 0.922a 70.59 0.535a 67.58 0.487a 71.01 0.532a 
III 13 69.98  71.79  70.01  72.00  
IV 2 73.10  77.64  75.73  79.98  
          
Microsatellite instability 
MSS 16 67.31 0.431 67.58 0.141 63.52 0.093 67.32 0.189 
MSI 6 72.15  73.71  72.36  74.37  
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Analysis of LINE-1 methylation and clinicopathological 
features using FFPE tissues  
 It was previously reported that LINE-1 hypomethylation is associated with tumor 
metastasis because it promotes liver metastasis in colorectal cancer [50]. One of 
results from our analysis using frozen tissues was that LINE-1 hypomethylation was 
associated with the presence of lymphatic invasion. In gastric cancer, there are 
several patients who are diagnosed with early gastric cancer with high number of 
lymph node metastasis, and there are also patients with advanced gastric cancer who 
have no lymph node metastasis. Therefore, we used 25 FFPE tumor tissues including 
13 tissues from advanced gastric cancer without lymph node metastasis (T3/4N0) 
and 12 tissues from early gastric cancer with > 7 regional lymph node metastases 
(T1N3). When we compared LINE-1 methylation level between two groups, there 
was no significant difference (p = 0.211, Figure 28). Accordingly, to assess if LINE-
1 methylation is related to certain other clinicopathological features, we further 
analyzed correlation between the methylation level and other clinicopathological 
parameters. As shown in Figure 29, LINE-1 methylation was significantly different 
according to tumor location (p = 0.008) and venous invasion (p = 0.017). In analysis 
of LINE-1 methylation level at each CpG site (Table 7), the methylation level at 
CpG1 was significantly lower in patients older than 57 years than in patients younger 
than 57 years and also significantly different according to the tumor location. In 
particular, the methylation levels at CpG1 and CpG2 were significantly lower in the 
lower third region than in middle third region. In case of venous invasion, the 
significant differences were shown at CpG2, CpG3 and CpG4.   
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Figure 29. LINE-1 methylation levels according to tumor location (A) and 
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Table 7. The methylation level of LINE-1 at four CpG site according to 
clinicopathological characteristics of FFPE tumor tissues 
Characteristic No 
LINE-1 methylation level (%) 
CpG1 P value CpG2 P value CpG3 P value CpG4 P value 
Type          
T3/4N0 13 73.78 0.207 73.64 0.250 76.84 0.446 83.98 0.226 
T1N3 12 77.26  75.57  78.91  87.31  
          
Age          
≤57 14 77.85 0.043 74.57 0.997 79.09 0.293 85.56 0.991 
>57 11 72.40  74.56  76.23  85.60  
          
Gender          
Male 12 75.25 0.889 74.23 0.707 76.88 0.500 85.16 0.774 
Female 13 75.64  74.87  78.72  85.96  
          
WHO classification 
Differentiated 6 71.51 0.103 74.04 0.870 75.71 0.384 87.09 0.487 
Undifferentiated 15 76.97  74.40  78.70  84.60  
          
Lauren classification 
Intestinal 8 71.58 0.090 74.28 0.955 76.07 0.518 87.35 0.300 
Diffuse 15 76.55  74.18  77.96  84.14  
          
Tumor location          
Upper 5 75.44 0.014a 73.59 0.156a 75.17 0.252a 82.11 0.367a 
Middle 5 82.75 0.002b 77.73 0.008b 81.95 0.080b 88.19 0.319b 
Lower 15 73.02  73.83  77.35  85.87  
          
Lymphatic invasion 
Not identified 11 75.68 0.883 74.01 0.563 78.12 0.856 85.54 0.982 
Present 14 75.27  75.00  77.62  85.61  
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Venous invasion 
Not identified 22 76.11 0.189 75.17 0.042 79.10 0.007 86.67 0.025 
Present 3 70.56  70.10  68.56  77.58  
          
Perineural invasion 
Not identified 12 77.65 0.120 75.24 0.440 78.52 0.631 85.69 0.939 
Present 13 73.41  73.94  77.21  85.47  
          
TNM stage          
II 23 75.49 0.919 74.82 0.309 77.99 0.703 86.02 0.274 
IV 2 74.97  71.67  76.07  80.47  
          
Microsatellite instability 
MSS 14 75.15 0.379 73.66 0.826 77.21 0.852 83.57 0.555 
MSI-high 3 71.06  74.33  76.34  86.53  
 
a ANOVA test 







- 71 - 
 
LINE-1 methylation and venous invasion of gastric cancer 
 In both frozen and FFPE tumor tissues, LINE-1 was significantly hypomethylated 
in the presence of venous invasion compared to those in the absence of venous 
invasion. To evaluate if LINE-1 hypomethylation can be an epigenetic marker for 
venous invasion of gastric cancer, we additionally analyzed its methylation status in 
combined frozen and FFPE tumor tissues. We also combined the methylation levels 
at CpG1 and CpG4, since it was reported that the combination of LINE-1 
methylation levels at CpG1 and CpG4 is useful marker for gastric cancer prognosis 
[54]. In the results, LINE-1 was significantly hypomethylated in the presence of 
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Figure 30. Combination analysis in venous invasion. Combination of the 
methylation levels in frozen and FFPE tissues (p = 0.001) (A) and combination of 
the methylation levels at CpG1 and CpG4 (frozen tissues; p = 0.018, FFPE tissues; 
p = 0.038, combined; p = 0.002) (B) 
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Discussion 
1. miR-30a/target gene expressions and LINE-1 methylation in gastric cancer 
In the present study, we used RNA sequencing data from TCGA, that large sample 
numbers of stomach adenocarcinoma are included, to confirm expression pattern of 
miR-30 family in gastric cancer. Among them, miR-30a was the most significantly 
downregulated compared with other members. Generally, hsa-miR-30a have two 
mature forms, miR-30a (miR-30a-5p) and miR-30a* (miR-30a-3p). In our in vivo 
experiments, we used stable cells overexpressing stem-loop sequence of miR-30a. It 
means two mature forms can affect the tumorigenesis in nude mice. When we 
validated their expressions in xenograft tumors using qRT-PCR, both forms were 
highly expressed in stable cells overexpressing miR-30a (data not shown). Other in 
vitro experiments were specifically performed about miR-30a-5p. Thus, we consider 
that miR-30a-5p has tumor suppressive functions in gastric cancer.  
We identified novel candidate target genes of miR-30a, ITGA2, FBXO45, 
ADAM19 and SEC23A, by microarray technique. This study has focused on ITGA2 
as a promising target of miR-30a because it was commonly upregulated in tumor 
tissues in both TCGA and our cohort. ITGA2 is one of family members of integrin, 
which is a transmembrane receptor for cell adhesion by forming a heterodimer with 
integrin beta subunits. ITGA2 expression can be epigenetically regulated by 
methylation or miRNAs, then it induces cell migration in cancer [56-59]. Shigeru et 
al. reported integrin α2 promotes migratory and invasive abilities of cancer cells by 
forming heterodimer with integrin β1 [60]. Another study showed that expression of 
α2β1 integrin is increased in peritoneal gastric cancer [61]. Recently, ITGA2 was 
revealed as an increased gene in advanced and metastatic gastric cancer as well [62]. 
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In our previous study, ITGB1 was directly targeted by miR-29c and suppressed 
gastric carcinogenesis [63]. Accordingly, combination of mR-29c and miR-30a 
might be a crucial factor for gastric cancer treatment. 
Although we have performed functional studies only for ITGA2, other three genes, 
FBXO45, ADAM19 and SEC23A may be promising targets for further study 
because they were also upregulated in gastric cancer compared to normal in TCGA 
data not in our tissue cohort. So far, few studies have revealed about their functions 
in cancer. Decreased FBXO45 expression is oncogenic in gastric cancer [64], but 
other two genes have been not reported about their tumor-associated functions in 
gastric cancer. Oncogenic ADAM19 is associated with metastasis in angiosarcoma 
[65], and SEC23A promotes secretome and metastasis of breast cancer cell [66]. 
Tissue samples from patients are obtained for various purposes, so they were 
preserved in various forms with/without pre-treatments according to the purposes. 
To pathologically examine gastric cancer tissues, formalin-fixation and paraffin-
embedding are performed. After paraffin block preparation, sections are used for 
histological review. For gene- or protein-based analyses such as expression analysis, 
and pyrosequencing, tissue samples were usually stored in liquid nitrogen without 
any pre-treatment as soon as possible after gastrectomy.  
In DNA methylation analyses, formalin fixation can affect bisulfite modification 
because formaldehyde can cause sequence artifacts such as cytosine deamination 
[67]. Thus, DNA methylation can be different according to tissue-storage conditions. 
In previous studies, certain clustered methylation patterns were differentially shown 
between frozen and FFPE tissues of colon [68], and the MGMT promoter was 
differentially methylated between two types of glioblastoma tissue samples [69]. In 
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gastric cancer, LINE-1 was significantly hypomethylated in fresh/frozen tissues than 
in paired FFPE tissues [54]. 
As a previous study, quantitative bisulfite pyrosequencing is one of useful methods 
to measure DNA methylation levels in biomarker studies [70]. For LINE-1 
methylation analysis, diverse methods, such as combined bisulfite restriction 
analysis, MethyLight and bisulfite pyrosequencing, have been used. Particularly, 
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2. Evaluation of miR-30a and LINE-1 as markers for clinicopathological 
features of gastric cancer 
H. pylori causes precancerous progression and carcinogenesis of gastric cancer, and 
especially in 60% of gastric adenocarcinoma, intestinal type gastric cancer is 
triggered through intestinal metaplasia and dysplasia after H. pylori infection [74]. 
It also induces MSI of gastric cancer [75], and MSI with H. pylori infection may 
induce gastric carcinogenesis [76]. miR-30a downregulation causes HNF4γ 
upregulation in intestinal metaplasia [33]. In our results, expression of miR-30a and 
ITGA2 is considered as genes which may be affected by H. pylori infection, MSI 
and histological type of gastric cancer. We found that miR-30a was downregulated 
in H. pylori infected, MSI-high and intestinal type gastric cancer. miR-30a was 
recently reported as a tumor suppressor in H. pylori-induced gastric cancer [77]. In 
contrast, ITGA2 was upregulated in MSI-high and intestinal type gastric cancer. 
Therefore, miR-30a-ITGA2 dysregulation may contribute to MSI-high gastric 
cancer affected H. pylori after miR-30a-HNF4γ-affected metaplasia, especially 
intestinal type of gastric cancer, because both ITGA2 mRNA and cytoplasmic 
ITGA2 were highly identified in intestinal type. 
LINE-1 methylation status can be a marker for detecting early gastric cancer as well 
as advanced gastric cancer using FFPE tissues [54, 78]. Particularly, it has been 
identified that LINE-1 methylation can be a marker for venous invasion in frozen 
tissues of lung cancer [79] and in serum samples of hepatocellular carcinoma [80]. 
Vascular invasion can induce tumor angiogenesis, lymph node metastasis and distant 
metastasis in gastric cancer [81]. Thus, finding biomarkers for vascular invasion in 
gastric cancer are needed to predict tumor metastasis. In our result, LINE-1 
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hypomethylation can be a marker for venous invasion in irrespective of tissue types. 
Further studies may be needed to assess the utility of serum samples for non-invasive 
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3. Conclusion 
To the best our knowledge, the present study is the first study which identified novel 
candidate target genes of miR-30a including ITGA2 based on microarray technique 
and which evaluated the association between miR-30a-ITGA2 expression and 
various clinical factors in gastric cancer. In conclusion, each miR-30a and ITGA2 
has a role of regulating gastric cancer cell growth and motility. Clinicopathologically, 
miR-30a-ITGA axis can be an independent biomarker for H. pylori infection and 
MSI of gastric cancer, and both ITGA2 mRNA and cytoplasmic ITGA2 are 
upregulated in intestinal type gastric cancer. This study highlighted that miR-30a-
ITGA2 may be a therapeutic target and biomarker for prediction of gastric 
carcinogenesis and prognosis. 
Our LINE-1 study is also the first to investigate associations between LINE-1 
methylation status and clinicopathological factors using both frozen and FFPE 
tissues of gastric cancer. Our limitations are as follows: (i) FFPE tissues consist of 
specific T and N stages such as T1N3 and T3/4N0. (ii) Small sample sizes were used. 
Therefore, validation study using more samples is needed. In conclusion, this study 
validated the methylation pattern of LINE-1 in frozen tissue samples which were not 
paired with FFPE tissue samples, and LINE-1 methylation status was related to 
several clinicopathological parameters in each sample set. The LINE-1 methylations 
in frozen tissues were different according to gender, differentiation, lymphatic and 
venous invasions, and the LINE-1 methylations in FFPE tissues were different 
according to tumor location and venous invasion. This study implies that LINE-1 
methylation can be a marker for several clinicopathological features in each tissue 
type and for venous invasion in both gastric cancer tissue types.  
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요약(국문초록) 
배경: 위암에서 마이크로RNA (miRNA) 나 DNA 메틸화와 같은 후성적 유
전자 변화는 암세포의 특성을 조절하는 주요 인자이며, 여러 유전자의 
발현을 조절함으로써 세포의 증식, 분화 및 세포사멸 등을 조절할 수 있
다. miRNA와 같은 small RNA는 Long interspersed nuclear element-1 
(LINE-1) 이라는 전이성 유전인자의 역전위에 의해 발생되기도 하는데, 
DNA 메틸화에 의해 LINE-1 과 같은 전이성 유전인자가 억제될 수 있다. 
miR-30a는 위암에서 저발현 되어 있지만 아직 그 생물학적 기능과 임상
적인 의의가 많이 밝혀져 있지 않고, LINE-1은 주로 암에서 저메틸화 되
어 있다고 알려져 있는데 특히 LINE-1 억제가 miR-30a의 발현 증가와 
관련이 있다는 보고가 있다.  
목적: 본 연구는 위암에서 miR-30a 발현과 LINE-1 메틸화 패턴을 확인하
고 miR-30a의 위암 특이적인 타겟 유전자를 찾음으로써 그 생물학적 기
능을 조사하고자 하였다. 또한 위암 환자에서의 임상적 의의를 평가함으
로써 miR-30a와 LINE-1의 진단 또는 예후 마커로서의 이용가능성을 평
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가하고자 하였다.  
방법: miR-30a와 타겟 유전자의 발현 확인을 위해 위암 환자 조직을 이
용한 qRT-PCR을 시행하였고, TCGA와 NCBI GEO 데이터를 통해 발현을 
검증하였다. 위암세포주에 miR-30a-5p를 과발현 또는 억제하여 생물학
적 기능 연구를 시행하였으며, in vivo 실험을 위해 stable cell line을 제작
하였다. Microarray 기법을 통해 miR-30a의 위암 특이적 타겟 유전자를 
확인 후 siRNA를 이용하여 in vitro 실험을 시행하였다. LINE-1 메틸화 연
구에서는 파라핀 조직 및 동결 조직을 이용하여 pyrosequencing을 통해 
4개의 LINE-1 CpG 부위의 메틸화 정도를 분석하였다. 최종적으로 유전자 
발현 및 메틸화 정도에 따른 위암 환자의 임상병리데이터를 분석하였다. 
결과: 위암 조직에서 miR-30a가 저발현 되어 있었고, LINE-1은 저메틸화 
되어 있었다. miR-30a가 ITGA2 유전자의 3’ UTR 부위에 결합하여 직접적
으로 발현을 조절함을 확인하였고, 위암 세포주에 miR-30a-5p를 과발현 
시키거나 ITGA2를 억제했을 때 세포 성장과 이동성, 콜로니 형성 능력이 
모두 감소하였다. 특히 miR-30a와 ITGA2가 Helicobacter pylori 감염이 
있는 위암 환자 및 Microsatellite instability가 높은 위암 환자, 그리고 장
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형 위암 (Intesinal type) 에서 통계적으로 유의한 관련성을 보였다. 동결 
조직과 파라핀 조직에서 LINE-1 메틸화를 분석했을 때, 두 종류의 조직
에서 LINE-1 메틸화가 다르게 나타났다. 동결 조직에서는 LINE-1 메틸화
가 환자의 성별, 조직의 분화도, 종양의 림프 및 정맥 침윤과 관련이 있
었고, 파라핀 조직에서는 종양 위치 및 정맥 침윤과 관련이 있었다.  
결론: 본 연구 결과 위암에서 miR-30a 발현이 감소되어 있고 miR-30a와 
그 타겟 유전자인 ITGA2가 위암 세포의 특성을 조절하였다. miR-30a를 
조절하는 인자 중 하나인 LINE-1 또한 분석한 조직 종류에 따라 몇 가지 
임상병리학적 특성에 따른 메틸화 마커로서 사용될 수 있고, 조직 종류
에 관계 없이 종양의 정맥 침윤 마커로서 사용될 수 있다. 그러므로 
miR-30a-ITGA2 및 LINE-1이 위암의 치료 및 예후 예측을 위한 전략이 
될 수 있을 것이다.   
주요어: 후성적 조절, miR-30a, 종양 억제 유전자, ITGA2, LINE-1, 정맥 침
윤, 위암 
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